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Summary
INTRODUCTION: Smoking bans are considered one of
the most effective policies to reduce population exposure
to tobacco smoke and prevent adverse health outcomes.
However, evidence on the effect of contextual variables on
the effectiveness of smoking bans is still lacking.
AIMS: The patchwork of cantonal smoke-free laws in
Switzerland was used as a quasi-experimental setting to as-
sess changes after their introduction in: hospitalisations and
mortality due to cardiorespiratory diseases in adults; total
hospitalisations and hospitalisations due to respiratory dis-
orders in children; and the modifying effects of contextual
factors and the effectiveness of the laws.
METHODS: Using hospital and mortality registry data for
residents in Switzerland (2005–2012), we conducted
canton-specific interrupted time-series analyses followed
by random effects meta-analyses to obtain nationwide
smoking ban estimates by subgroups of age, sex and causes
of hospitalisation or death. Heterogeneity of the impact
caused by strictness of the ban and other smoking-related
characteristics of the cantons was explored through meta-
regression.
RESULTS: Total hospitalisation rates due to cardiovascular
and respiratory diseases did not significantly change after
the introduction of the ban. Post-ban changes were detected
in ischaemic heart disease hospitalisations, with a 2.5% re-
duction (95% confidence interval [CI)] −6.2 to 1.3%) for
all ages and 5.5% (95% CI −10.8 to −0.2%) in adults 35–64
years old. Total mortality due to respiratory diseases de-
creased by 8.2% (95% CI −15.2 to −0.6%) over all ages,
and chronic obstructive pulmonary disease mortality de-
creased by 14.0% (95% CI −22.3 to −4.5%) in adults ≥65
years old. Cardiovascular mortality did not change after
the introduction of the ban, but there was an indication of
post-ban reductions in mortality due to hypertensive disor-
ders (−5.4%, 95% CI −12.6 to 2.3%), and congestive heart
failure (−6.0%, 95% CI −14.5 to 3.4%). No benefits were
observed for hospitalisations due to respiratory diseases in
children or for infant mortality. The type of smoking ban
implemented explained the heterogeneity of benefits across
cantons for some outcomes.
CONCLUSION: Smoking bans in Switzerland were asso-
ciated with overall reductions in cardiovascular and respir-
atory hospitalisation and mortality in adults.
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Introduction
Together with increased tobacco prices, smoking ban are
one of the most effective policies to reduce exposure to to-
bacco smoke and prevent related adverse health outcomes
[1]. There is now a large body of evidence showing that
the implementation of smoking bans may considerably re-
duce cardiovascular hospitalisations, especially those due
to acute myocardial infarction, worldwide [2–5]. Although
less explored, smoking bans have also been shown to par-
ticularly benefit vulnerable populations such as children,
pregnant women and the elderly [6–9]. Recent evidence
suggests that smoking bans protect nonsmokers from the
harm of passive smoking, with a more pronounced effect
from more comprehensive laws [10, 11]. Smoking bans
have also been associated with active-smoking reduction
and cessation [12, 13]. Despite this evidence, 18% of the
world population, including residents in only eight
European countries, live in regions with comprehensive na-
tional smoke-free laws. Most implemented partial laws do
not fully protect the population from passive smoke ex-
posure in public places (i.e., allow smoking in restricted
areas in hospitality venues with service of a specific size)
[14]. A better understanding of vulnerabilities of the popu-
lation and other contextual factors (i.e. chronic health con-
ditions, socioeconomic profile, smoking behaviours) influ-
encing the effectiveness of the laws in different contexts
is needed to better support worldwide implementation of
smoking bans and further strengthen antitobacco laws.
In Switzerland, smoking in public places and workplaces is
regulated at both the national and cantonal level (cantons
are the largest administrative units of the Swiss Federal
state). In May 2010, the Swiss parliament approved a na-
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tionwide federal smoking ban covering indoor public
places and workplaces, but with several exceptions in the
hospitality sector (authorised smoking establishments <80
m2 and dedicated smoking rooms in larger establishments).
When the federal ban was enacted, 12 out of 26 cantons
had previously introduced their own laws as early as 2007,
some with a higher level of protection for hospitality work-
ers (fig. 1; fig. S1 in appendix 1: supplementary figures
and tables). This patchwork of regulation is an ideal natural
experiment to explore the health impact of contextual as-
pects of the regulations. Except for a nationwide study on
pregnancy outcomes [15], only a few small canton-spe-
cific studies on the health effects of the smoking ban ex-
ist in Switzerland. These past studies evaluated principally
changes in hospital admissions for acute myocardial in-
farction after the laws came into force, and rarely focused
on other outcomes, such as respiratory diseases [16–19].
In addition, none could address other questions related to
mechanisms influencing the effectiveness of the smoking
ban.
This study aimed at providing, for Switzerland, a compre-
hensive picture of the changes in mortality and hospitalisa-
tions due to cardiorespiratory diseases in adults and chil-
dren achieved after the introduction of the smoking bans.
We also aimed to give more evidence on the potential
mechanisms explaining the variable effectiveness of the
laws according to characteristics of the population.
Methods
Population and outcomes
We evaluated the cantonal and nationwide impact of
smoke-free laws in Switzerland using hospital admissions
and mortality data for Switzerland between 2005 and 2012
from the Health Registry of the Swiss Federal Statistical
Office (Bundesamt für Statistik, BFS). All cases among
Swiss residents were aggregated into monthly counts in
each study year (according to the date of death or hospital-
isation) by canton, gender, age group (children if ≤15 years
old, adults if ≥35 years old) and specific causes. People
aged between 16 and 34 years (inclusive) were not included
in the adult category because of their different physiology
and behaviour towards tobacco. Only emergency hospital
admissions were considered.
The cardiovascular and respiratory outcomes considered in
adults (≥35 years old), categorised according to the Interna-
tional Classification of Diseases Tenth Revision (ICD-10),
were: ischaemic heart disease (IHD) (I20–I25), cerebrovas-
cular diseases (I60–I69), hypertensive disorders (I10–I15),
arrhythmia (I47–I49), congestive heart failure (I50), chron-
ic obstructive respiratory disease (COPD) (J40–J44, J47),
asthma (J45–J46) and pneumonia (J12–J18). We conducted
subanalyses for total myocardial infarction cases (I21),
with ST-elevation (STEMI) (I210–I213) and without ST-el-
evation (NSTEMI) (I214). Stratified analyses in adults per
subcategory of age (adults between 35 and 64 years of age,
and ≥65 years old) and gender were performed.
We restricted the analysis in children (≤15 years old) to
hospital admissions due to respiratory infections (J00–22),
and total infant mortality (<1 year of age) and mortality due
to perinatal conditions (P00–96). We did not consider other
causes of death or hospitalisation in this age group because
the number of cases per month and canton was too small.
The causes of death or hospitalisation, definitions and age
groups included in our study are presented in table S1 (ap-
pendix 1). The selection of these groups of causes was
based on previous smoking-ban studies and in order to
cover a wider spectrum of diseases, population subgroups,
mechanisms and degrees of vulnerability.
Analysis of overall effects
We performed canton-specific interrupted time-series ana-
lyses to estimate the changes in mortality and hospital ad-
missions after the introduction of the smoking ban in each
canton, by age group and main cause category. Quasi-Pois-
son regression models were applied, and the smoking ban
impact was modelled with a step function (by assigning a
value of one to the months of the ban period and zero to
pre-ban months, according to the specific date of introduc-
tion in each canton) following the usual approach of in-
terrupted time-series design. We controlled for long-term
trends (by a linear function of calendar time, consisting in
a continuous series from first day of the pre-ban period to
the last day of the smoking ban period in each canton-spe-
cific model), seasonality (with a four-level categorical vari-
able, representing the different seasons), influenza peaks
(by linear function of the monthly mean consultation rates
of influenza-like illnesses for each canton, provided by the
BAG Bundesamt für Gesundheit), and number of days of
the month (as logarithm). Age- and gender-specific annu-
al population for each canton was introduced as offset. Be-
cause some cantons introduced their own smoke-free laws
at different timepoints prior to the federal legislation, the
main analysis was restricted to periods of 2 years before
and 2 years after the date of implementation of the law in
the corresponding canton (fig. S1, appendix 1). This as-
sumption was relaxed in a sensitivity analysis (see below).
We also tested serial autocorrelation of residuals across 24
lags for each of the cantonal time series models, using the
partial autocorrelation function.
We performed random-effect meta-analyses of the canton-
specific estimates to obtain the nationwide percent change
in mortality and hospitalisation rates after the implement-
ation of the smoking bans. The heterogeneity between the
canton-specific results was assessed with I2 statistics and
the test of heterogeneity. Through visual inspection of the
temporal trends, we identified and excluded from each
cause-specific analysis those cantons showing inconsistent
or unexplainable changes through time.
Analysis of effect modification
We used meta-regression to explore potential modifications
of impacts related to the extent and severity of smoking
bans: that is, we differentiated between cantons following
only the federal smoking ban (“federal law”) and those
with more prohibitive bans and additional occupational ex-
posure restrictions (“federal law + restrictions”) (fig. 1).
We also examined whether impacts of the smoking ban
were related to changes in cantonal levels of active and
passive smoking after the bans by applying the same stat-
istical procedure. These data were obtained from two dif-
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ferent rounds of the Swiss Health Survey, in 2007 and 2012
(http://www.bfs.admin.ch/bfs/portal/de/index/infothek/er-
hebungen__quellen/blank/blank/ess/04.html). This is a
population-based survey performed every 5 years that col-
lects information on health status and habits from a repres-
entative sample of Swiss residents aged 15 years or over.
Cantons whose prevalence of reported active smoking had
decreased between the two survey years were compared
with cantons that did not show a decrease. Given that all
cantons experienced a decrease in passive smoking during
the study period, we compared groups of cantons according
to whether this decrease in passive smoking was above or
below the overall median value. All meta-regression ana-
lyses were adjusted by the socioeconomic and health pro-
file of the population in each canton, because previous
studies reported socioeconomic disparities in smoking ban
effectiveness or level of coverage [20, 21]. Methods have
been described elsewhere [15]. Briefly, two independent
scores were developed by principal component analysis of
several socioeconomic and health indicators collected at
cantonal level and jointly included in the meta-regression
models as linear functions.
Sensitivity analysis
We performed several sensitivity analyses to check the ro-
bustness of our results: (1) we introduced the canton-spe-
cific monthly count of a “non-smoking-ban related out-
come” (see definition below) as explanatory variable to
additionally capture the baseline trends in hospitalization
and mortality rates in each canton, (2) we did not restrict
the post- and pre-ban study periods to 2 years, (3) no canton
was excluded from the meta-analysis, (4) we simulated a
“fake” smoking ban preceding the true one by 1 year in
each canton and we restricted the study period to 1 year
before and 1 year after this to exclude the true smoking
ban date from this analysis, (5) we estimated the smoking
ban impact on a control or “non-smoking-ban related” out-
come, which we assumed not to be associated with the
ban. For this purpose, we selected deaths due to external
causes (V01–Y98) and hospital admission due to injuries
(S00–S98). To avoid multiple comparisons, meta-regres-
sion and sensitivity analyses were conducted only on hos-
pitalisations and mortality due to IHD and COPD as the
two main outcomes representative of the smoking ban im-
pact on health in adults, as shown in several previous stud-
ies [22–24].
All analyses were conducted with statistical software R
(Team R Development Core) and STATA (StataCorp, Col-
lege Station. TX).
Results
All supplementary figures and tables are presented in ap-
pendix 1.
During the restricted period of 2 years before to 2 years
after the introduction of the smoking ban in each canton in
Switzerland, there were a total of 365 283 hospitalisations
due to cardiovascular diseases and 111 043 due to respirat-
ory diseases in adults (≥35 years old), with a monthly aver-
age of 208 and 87 cases per canton, respectively (table 1).
Hospitalisations due to IHD, COPD and pneumonia were
the most frequent, representing 26%, 20% and 45%, re-
spectively, of total hospitalisations due to cardiovascular or
respiratory diseases. Cardiovascular mortality amounted to
87 833 cases (69 cases per month and canton) and mor-
tality due to respiratory diseases to 15 142 (12 cases per
month and canton). We found that hospitalisation and mor-
tality rates were in general higher for males (except for
asthma hospital admissions) and in the older age category
(≥65 years old) with over 90% of the deaths occurring in
this age group (table S2).
Nationwide smoking ban estimates for outcome groups in
adults (≥35 years) are reported in table 1. Before graphic-
al display of the data, we excluded the cantons of Aargau
Figure 1
Geographical distribution of the two types of smoking ban
implemented in each canton in Switzerland. Fed. Law (light grey):
cantons which followed only the Federal Smoking Ban; Fed. Law +
restrictions (dark grey): cantons which applied additional
restrictions to the Federal Smoking Ban.
Figure 2
Gender- and age-specific estimates of percentage (and 95%
confidence intervals, CIs) change in hospital admissions and
mortality in adults (≥35 years old) by the main groups of causes
after the introduction of the smoking ban (data restricted to the
periods 2 years before and 2 years after the introduction of the
smoking ban in each canton).
COPD = chronic obstructive pulmonary disease; SB = smoking ban
Hospital admissions: Canton Aargau was excluded from the meta-
analysis of cardiovascular diseases, ischaemic heart disease,
cerebrovascular diseases; Canton Bern was excluded from the
meta-analysis of hypertensive disorders, arrhythmia, congestive
heart failure.
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and Bern from the meta-analysis for hospital admissions
for some specific cardiovascular causes because of sudden
unexplained changes in trends (detailed list in a footnote to
table 1, monthly time trends of the cantonal outcomes ex-
cluded from meta-analysis in figure S2). Whereas canton-
specific mortality estimates seemed to be homogeneous,
large variability was found for hospitalisations, with stat-
istically significant heterogeneity for most of the outcomes
(except IHD, arrhythmia, COPD and asthma) (table S3, fig.
S3).
Overall, hospitalisation rates for the main cardiovascular
and respiratory causes did not significantly change after the
introduction of the ban. However, we found a reduction by
−2.5% (95% confidence interval [CI] −6.2 to 1.3%) in IHD
hospital admissions over all ages, with a stronger decrease
detected in adults between 35 and 65 years old (−5.5%,
95% CI −10.8 to 0.2%) (fig. 2, numerical data in table S4).
This was confirmed with consistent reductions in hospital-
isations due to STEMI (−7.3%, 95% CI −13.2 to −1.0%) in
35- to 65-year-old adults (table S5).
Respiratory mortality decreased by −8.2% (95% CI −15.2
to −0.6%) following the introduction of the bans, with lar-
ger reductions for COPD of up to −13.9% (95% CI −22.3
to −4.5%) in all age groups, and −13.4% (95% CI −21.7 to
−4.18%) in adults ≥65 years old (fig. 2). Smaller, nonsig-
nificant reductions in cardiovascular mortality were ob-
served, with some indication of an effect on mortality for
hypertensive disorders in females (−7.5%, 95% CI −17.0
to 3.1%, p = 0.195), and congestive heart failure in males
(−11.1%, 95% CI −24.4 to 4.5%, p = 0.192).
Figure 3
Change (and 95% confidence interval, CI) in hospital admissions
and mortality due to ischaemic heart disease and chronic
obstructive pulmonary disease (COPD) in adults (≥35 years old)
after the introduction of the smoking ban, by type of law and
smoking profile of the canton (adjusted for the socioeconomic and
health profile of the population).
SB = smoking ban.
Type of law: Fed. Law = cantons which followed only the federal
smoking ban, Fed. Law + restr = cantons which applied additional
restrictions to the federal smoking ban.
Change in active smoking: difference between the reported
smoking prevalence in the Swiss Health Surveys of 2007 and 2012.
Stratified by non-decrease vs decrease in prevalence.
Decrease in environmental tobacco smoke (ETS) exposure:
difference between the reported ETS exposure in the Swiss Health
Surveys of 2007 and 2012. Since there was always a decrease,
cantons were classified according to whether the decrease was
above or below the median value.
Results for infant mortality and respiratory hospital admis-
sions in children were inconsistent, with large confidence
intervals (table S6).
We found some heterogeneity of effects by type of smoking
ban implemented. There were greater reductions in hospit-
alisations due to IHD and COPD in cantons applying more
restrictive smoking bans. We found a reduction in hospital-
isation for IHD of 3.1% (95% CI −8.2 to 2.2%) for cantons
with federal law + restrictions vs a null effect of 0.5% (95%
CI −8.6 to 10.5%) for cantons with federal law only. In hos-
pitalisation for COPD, we found a 5.3% (95% CI −13.7 to
3.8%) reduction in cantons with federal law + restrictions,
but there was no effect for cantons with federal law only
(9.1%, 95% CI −7.1 to 18.2%). In both cases, however, dif-
ferences between categories of type of ban were not statist-
ically significant (fig. 3, numerical results in table S7).
For IHD, similar patterns were observed when changes
in smoking-related exposure characteristics of the cantons
after the ban were used in the meta-regression instead of
type of ban implemented. For example, the benefits of the
ban were limited to cantons reporting a reduction in active
smokers during the period when smoking bans were im-
plemented, and cantons with a larger decrease in passive
smoking exposure showed stronger post-ban reductions in
hospitalisations (IHD hospitalisation: −6.3%, 95% CI
−11.2 to −1.2% in cantons with higher than median de-
crease vs 2.3%, 95% CI −3.3 to 8.2% in cantons with de-
creases equal to or lower than the median change, p-value
for the interaction 0.04). In addition, we found some het-
erogeneity of effects for IHD mortality. IHD mortality de-
creased by 6.8% (95% CI −12.2 to 1.1%) in cantons with
a higher than median decrease in passive smoking expos-
ure, but there was no effect in cantons with decreases equal
to or lower than the median change (4.8%, 95% CI −1.9
to 12.0%, p value for the interaction 0.02). Compared with
IHD, the effect of the smoking ban on COPD varied little
when using smoking-related cantonal characteristics other
than type of ban.
The results of sensitivity analysis are reported in table S8
for the two selected representative outcomes. Smoking ban
estimates did not vary significantly when applying addi-
tional control for time trends (sensitivity analysis [SA]1).
Except for IHD mortality, there was a decrease in the ef-
fects of the smoking ban when the study period was ex-
tended from 2005 to 2012 for all cantons (SA2). Similarly,
the smoking ban estimate for IHD hospitalisations became
smaller and more uncertain when all cantons were included
in the model (SA3). Overall, significant changes were not
observed when the date of the introduction of the smoking
ban in each canton was displaced by 1 year (SA4), or when
the analysis was conducted with control outcomes (SA5).
We only found a significant reduction in COPD hospital-
isations in SA4, which was mostly due to a very strong de-
crease in the biggest canton, Zurich (data not shown).
Discussion
Main findings
This is the first comprehensive nationwide study on the car-
diorespiratory effects of smoking bans in Switzerland. We
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found that the smoking bans were associated with nation-
wide reductions of −5.5% in hospital admissions for IHD
of adults between 35 and 65 years old, and −8% in respir-
atory mortality and −14% in COPD mortality in the oldest
adults. No benefit of the laws could be inferred for chil-
dren in terms of hospitalisations due to respiratory diseases
or infant mortality. The type of smoking ban implemented
explained the heterogeneity of benefits across cantons for
some outcomes.
The health benefits of smoking bans on cardiorespiratory
outcomes in Switzerland were previously assessed in small
studies performed in only 3 out of the 26 Swiss cantons
(Geneva, Ticino and Graubünden), which were among
those applying more comprehensive laws [16–19, 25].
Overall, our results confirm a nationwide benefit of
smoking bans in Switzerland for IHD hospitalisation, as
found in some of these previous local Swiss studies, al-
though comparison of magnitude of effects is difficult giv-
en the different methodology and modelling approaches
applied between our study and the local studies. Our over-
all estimate is consistent with results from past studies, par-
ticularly a recent review that found a reduction of 8% in
hospitalisations for acute coronary events from studies per-
formed in locations with only partial bans [2, 17–19, 22,
26, 27].
It is hypothesised that changes in active or passive tobacco
exposure induce physiological changes that increase the
risk of ischaemia and arrhythmias in the short term [28]. In
adults, the rapid benefits on IHD outcomes observed after
the smoking bans are explained by a rapid reduction in to-
bacco exposure, which quickly removes potential triggers
for acute cardiovascular outcomes [2]. We found that bene-
fits for IHD hospitalisations materialised in adults between
35 and 65 years old, an effect reported in only a few
previous studies [29]. In Switzerland, these people might
be considered to be a vulnerable group at increased risk
of an acute coronary event because they would not be
under pharmacological treatment or have healthier lifestyle
choices. This may explain in part why our study found
rapid benefits for this age group after implementation of
smoking bans.
Fewer studies have evaluated the association between res-
piratory outcomes in adults and smoking ban. Some studies
reported consistent reductions in respiratory admissions in
adults, but others, like us, did not [29]. However, our res-
ults are within the range of the reduction in COPD mortal-
ity of −38% in older adults found in a recent Irish study [9].
We found reductions in respiratory mortality from COPD
independently of the type of smoking ban implemented and
the magnitude of change in active and passive smoking at
population level. These individuals are probably at a very
vulnerable stage of their disease and are altogether more
susceptible to any small change in tobacco smoke expos-
ure [30]. We found some evidence of a reduction in mortal-
ity from hypertensive disorders and congestive heart fail-
ure. The major causes of death for patients with COPD or
chronic cardiovascular disorders include acute myocardi-
al infarction, heart failure, pulmonary embolism and cardi-
ac arrhythmia [31]. Although these deaths may be coded
on the basis of the main diagnosis, individuals with some
underlying chronic cardiorespiratory pathologies may be
more likely to die from related acute coronary outcomes
which could explain our findings. Our results point to a po-
tential underestimation of the benefits of the law on high-
risk, chronically ill patients; further investigation using re-
gistries that can better identify these individuals is needed.
Although we previously found strong evidence of the ef-
fects of the smoking ban on birth outcomes in Switzerland
[15], no impact of the bans on respiratory hospital admis-
sions of children and infant mortality could be detected
in this study. A recent meta-analysis reported a 10% re-
duction in asthma admissions in children [6], whereas an-
other study not included in this review found inconsistent
associations [32]. Our null findings might be due to the
low number of cases in each canton, and the use of other
data sources such as routine doctor registry data might
have been more suitable in order to capture not only the
more severe cases. It could also be possible that smoking
Table 1: Percent change in hospital admissions and mortality in adults (≥35 years) due to the main groups of causes after the introduction of the smoking ban (95%
confidence interval) (data restricted to the period including 2 years before and 2 years after the introduction of the smoking ban in each canton).
Hospital admissions MortalityCause of hospitalisation or death
(ICD-10 codes in parenthesis) N (%)* % change
(95% CI)†
p-value N (%)* % change
(95% CI)
p-value
Cardiovascular diseases (ICD-10:
I00–I99)
265 283 0.02 (−2.71 to 2.82) 0.990 87 833 −0.72 (−3.67 to 2.31) 0.623
Ischaemic heart diseases (I20–I25) 69 829 (26.3) −2.54 (−6.23 to 1.30) 0.183 33 880 (38.6) −1.38 (−5.98 to 3.45) 0.555
Cerebrovascular diseases (I60–I69) 48 420 (18.3) 0.78 (−6.55 to 8.69) 0.834 15 578 (17.7) −2.48 (−12.7 to 8.92) 0.644
Hypertensive disorders (I10–I15) 20 049 (7.6) 5.86 (−9.78 to 24.2) 0.469 10 679 (12.2) −5.43 (−12.6 to 2.27) 0.154
Arrhythmia (I47–I49) 25 096 (9.5) 2.46 (−5.72 to 11.4) 0.552 2 873 (3.3) 6.09 (−8.62 to 23.2) 0.422
Congestive heart failure (I50) 37 663 (14.2) −2.41 (−15.6 to 12.8) 0.731 7 061(8.0) −5.98 (−14.5 to 3.37) 0.192
Respiratory diseases (ICD-10:
J00–J99)
111 043 0.03 (−5.67 to 6.06) 0.993 15 142 −8.20 (−15.2 to −0.64) 0.035
Chronic obstructive pulmonary disease
(J40–J44, J47)
22 251 (20.0) −2.08 (−9.85 to 6.35) 0.604 7 308 (48.3) −13.9 (−22.3 to −4.54) 0.006
Asthma (J45–J46) 3 285 (3.0) 7.26 (−13.4 to 32.9) 0.506 406 (2.7)
Pneumonia (J12–J18) 50 377 (45.4) 0.22 (−8.92 to 10.3) 0.962 4 911 (32.4) −5.71 (−20.7 to 12.2) 0.492
CI = confidence interval; N = total number of cases
* Percentage of cases due to the specific cause within the respective main disease category. N = total number of cases.
† Canton of Aargau was excluded from the meta-analysis of cardiovascular diseases, ischaemic heart disease, cerebrovascular diseases; Canton of Bern was excluded
from the meta-analysis of hypertensive disorders, arrhythmia, congestive heart failure.
Statistically significant results (p <0.05) are in bold type.
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bans changed the behaviour of smokers in private places
(home, car, etc.) where children spend most of their time.
However, evidence for such a shift is still not totally con-
sistent and is unavailable for Switzerland [33–35].
Indication of larger impacts on IHD and COPD hospital-
isations was found in cantons that applied additional re-
strictions to the federal smoke-free law. These results sug-
gest consistent benefits for groups, such as those who are
more socially active or at employment age, experiencing a
more noticeable beneficial change in tobacco exposure in
restaurants and bars. It might be the case that hospitalised
populations are a priori less severe health state than those
at a more advanced stage of disease. Indeed, a differential
pattern of effect by smoking ban was not observed in mor-
tality estimates, which were based almost entirely on adults
of retirement age (more than 90% of the total number of
deaths) and who probably do not frequent hospitality ven-
ues regularly. Our results confirm that only more restrictive
smoking bans can reduce direct or indirect tobacco expos-
ure to sufficiently protect the population at large.
Strengths and limitations of the study
We believe our models are robust for several reasons. First,
it is unlikely that they are sensitive to potential changes co-
inciding with the smoking bans but unrelated to them be-
cause we capitalised on a quasi-experimental setting that
minimises this risk (smoking bans were implemented at
different time-points across cantons). The null findings
from the “fake” smoking ban analysis for most of the out-
comes and in the regular analysis of outcomes not related
to the smoking ban reinforce this assumption (sensitivity
analyses SA4 and SA5). We further considered regional
differences in health and socioeconomic profiles, with the
inclusion of the corresponding scores in the meta-regres-
sion analysis. To prevent potential selection bias, we used
routinely collected registry-based data, with nearly com-
plete coverage of the population in all cantons. If there
were any bias, our estimates would be an underestimation
rather than an overestimation of the ban effect. The im-
plementation of smoking bans in Switzerland entailed a
long legislative process, with the introduction in some can-
tons of partial anti-tobacco initiatives preceding the federal
smoke-free law or the more restrictive cantonal bans. To
simplify our analysis, a unique date of smoking ban in-
troduction, which corresponded to the time when the most
comprehensive smoke-free law was implemented, was as-
signed for each canton. However, we believe that the po-
tential effect of pre-ban initiatives on mortality and hos-
pitalisations would have been captured in our estimates as
well, given that most of them were introduced during the
2 years before the ban, which was considered in our ana-
lysis as control time. Further, exposure misclassification of
place of residence and mobility between cantons (commut-
ing due to work), probably produce an underestimation of
effect. Similar underestimation is expected from nondiffer-
ential misclassification of diseases.
Of note, estimates for IHD were slightly sensitive to the in-
clusion of a nonlinear function of time. Barr et al. previ-
ously raised the issue of the necessity to adjust for potential
nonlinear trends in order to prevent biased smoking ban es-
timates [36]. However, we consider the use of a linear time
trend to be suitable given the short pre- and post-ban peri-
ods (2 years) used, as others have suggested [3]. Moreover,
as we stratified analyses by canton, the use of nonlinear
functions of time might have absorbed some of the effects
of the smoking ban. We found significant heterogeneity
among canton-specific smoking ban estimates for most of
the causes of hospital admissions, although not for mortal-
ity. This different pattern might be related to coding dif-
ferences associated with the health system of each canton.
We acknowledge that our findings would be generalisable
only to other countries with similar population character-
istics, smoking habits and smoke-free laws. And finally,
based on our findings, we cannot differentiate between the
role of environmental tobacco smoke exposure at home and
in public spaces, and further studies using tobacco monitor-
ing data should be performed to better assess the contribu-
tion of each of the two main environmental tobacco smoke
sources to the overall impact of the smoking ban.
Conclusions
Smoking bans in Switzerland were associated with reduc-
tions in cardiovascular and respiratory hospitalisation and
mortality in adults. Our results also suggest that reduction
in passive and active smoking is one of the most relevant
predictors of the health impact of smoking bans, mainly for
IHD. The enforcement of even more comprehensive bans
at national level could contribute to reductions in passive
and active tobacco exposure sufficient to benefit the whole
population. Given the unique situation of smoking ban im-
plementation in Switzerland, we were able to provide a
more complete picture of the benefits, and simultaneously
address several research questions by exploring the region-
al heterogeneity of the effects according to the degree of
protection by the law and vulnerability profiles.
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Appendix 1: Supplementary tables and figures
Table S1: Causes of hospitalisation or death (according to ICD-10).
Population
Age
Main group ICD-10 code Subcategory ICD-10 Code
Ischaemic heart diseases I20–I25
Acute myocardial infarction I21
STEMI I210–I213
NSTEMI I214
Unstable angina I20
Chronic ischaemic heart disease I25
Congestive heart failure I50
Cerebrovascular I60–I69
Cardiovascular I
Hypertensive disorders I10–I15
Chronic lower respiratory diseases J40–J47
Chronic obstructive pulmonary disease J40–J44, J47
Asthma J45–J46
Respiratory J
Pneumonia J12–J18
External* V01–Y98
Adults ≥35 years
Injuries* S00–S98
Infants <1 year Total All Conditions originating in the perinatal period P00–P96
Children ≤15 years Respiratory J Respiratory infections J00–J22
ICD-10 = International Classification of Diseases Tenth Revision; NSTEMI = non-ST-elevation myocardial infarction; STEMI = ST-elevation myocardial infarction
* Outcomes not related to the smoking ban
Table S2: Description of the gender- and age-specific series of mortality and hospital admissions in adults (≥35 years old) for the main groups of causes (data restricted to
the period including 2 years before and 2 years after the introduction of the smoking ban in each canton).
Hospital admission MortalityCause of hospitalisation or death
(ICD-10 codes in parenthesis) N / %* Monthly mean N†
(SD)
N / %* Monthly mean N†
(SD)
Total 265 283 208.2 (214.0) 87 833 68.9 (73.5)
Male 55.7% 115.9 (117.9) 45.0% 31.0 (33.0)
Cardiovasculardiseases (I)
≥65 years 72.3% 57.6 (58.7) 92.6% 63.8 (68.3)
Total 69 829 54.8 (55.8) 33 880 26.6 (30.2)
Male 68.3% 37.4 (38.2) 52.6% 14.0 (15.8)
Ischaemic heart diseases (I20–I25)
≥65 years 60.7% 33.2 (34.5) 90.8% 24.2 (27.7)
Total 48 420 38.0 (41.0) 15 578 12.2 (13.6)
Male 53.2% 20.2 (21.8) 39.0% 4.8 (5.5)
Cerebrovascular diseases (I60–I69)
≥65 years 75.0% 28.5 (31.2) 94.4% 11.5 (13.0)
Total 20 049 15.7 (19.9) 10 679 8.4 (9.4)
Male 36.5% 5.7 (7.5) 33.2% 2.8 (3.3)
Hypertensive disorders (I10–I15)
≥65 years 78.9% 12.4 (16.3) 96.2% 8.1 (9.1)
Total 25 096 19.7 (21.1) 2 873 2.3 (2.8)
Male 50.8% 10.0 (11.0) 43.0% 1.0 (1.4)
Arrhythmia (I47–I49)
≥65 years 73.3% 14.4 (15.7) 92.8% 2.1 (2.6)
Total 37 663 29.6 (31.2) 7 061 5.5 (6.0)
Male 51.4% 15.2 (15.9) 35.9% 2.0 (2.4)
Congestive heart failure (I50)
≥65 years 90.1% 26.6 (28.2) 97.8% 5.4 (5.9)
Total 111 043 87.2 (95.8) 15 142 11.9 (12.8)
Male 55.4% 48.3 (52.1) 53.3% 6.3 (7.0)
Respiratory (J)
≥65 years 69.0% 60.1 (66.8) 92.7% 11.0 (11.9)
Total 22 251 17.5 (20.5) 7 308 5.7 (6.5)
Male 57.4% 10.0 (11.9) 59.5% 3.4 (4.1)
COPD (J40–J44, J47)
≥65 years 75.9% 13.2 (15.7) 91.9% 5.3 (6.0)
Total 3 285 2.6 (3.5) 406 0.3 (0.7)
Male 31.3% 0.8 (1.3) 25.9% 0.1 (0.3)
Asthma (J45–J46)
≥65 years 45.8% 1.2 (1.8) 88.4% 0.3 (0.6)
Total 50 377 39.5 (43.7) 4 911 3.9 (4.6)
Male 56.8% 22.5 (24.3) 45.7% 1.8 (2.3)
Pneumonia (J12–J18)
≥65 years 73.6% 29.1 (32.3) 95.1% 37. (4.4)
COPD = chronic obstructive pulmonary disease; ICD-10 = International Classification of Diseases Tenth Revision; N = total number of cases; SD = standard deviation
* Relative frequency related to the total number of cases due each specific cause
† Mean monthly number of cases in each canton
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Table S3: Assessment of heterogeneity within canton-specific results included in the meta-analysis.
Hospital admission* MortalityCause of hospitalisation or death
(ICD-10 codes in parenthesis) I2 Test for heterogeneity
p-value
I2 Test for
heterogeneity
p-value
Cardiovascular diseases (I) 13.5% 0.04 0.0% 0.79
Ischaemic heart diseases (I20–I25) 8.8% 0.68 7.6% 0.59
Cerebrovascular diseases (I60–I69) 45.1% <0.01 40.5% 0.01
Hypertensive disorders (I10–I15) 63.1% <0.01 0.0% 0.73
Arrhythmia (I47–I49) 26.5% 0.08 0.0% 0.67
Congestive heart failure (I50) 79.9% <0.01 0.0% 0.78
Respiratory diseases (J) 42.0% 0.02 0.0% 0.58
COPD (J40–J44, J47) 22.2% 0.29 0.0% 0.63
Asthma (J45–J46) 14.0% 0.06 – –
Pneumonia (J12–J18) 53.1% <0.01 21.2% 0.13
COPD = chronic obstructive pulmonary disease; ICD-10 = International Classification of Diseases Tenth Revision
* Canton Aargau was excluded from the meta-analysis of cardiovascular diseases, ischaemic heart disease, cerebrovascular diseases; Canton Bern was excluded from
the meta-analysis of hypertensive disorders, arrhythmia, congestive heart failure.
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Table S4: Gender- and age-specific percent estimates (and 95% confidence interval) in change in hospital admissions and mortality in adults (≥35 years old) due to the
main groups of causes after the introduction of the smoking ban (data restricted to the period including 2 years before and 2 years after the introduction of the smoking ban
in each canton). Results are displayed in figure 2.
Hospital admission* MortalityCause of hospitalisation or death
(ICD-10 codes in parenthesis) % change (95% CI) p-value p-value int† % change (95% CI) p-value p-
value
int†
Total 0.02 (−2.71 to 2.82) 0.990 −0.72 (−3.67 to 2.31) 0.623
Male 1.00 (−2.10 to 4.20) 0.517 0.205 −3.22 (−7.32 to 1.07) 0.133 0.171
Female −2.03 (−5.43 to 1.49) 0.242 1.19 (−3.43 to 6.03) 0.606
35–64 years old 0.14 (−3.56 to 3.99) 0.938 0.940 −2.44 (−14.17 to 10.89) 0.695 0.803
Cardiovascular
diseases (I)
≥65 years old −0.06 (−3.81 to 3.84) 0.974 −0.79 (−3.73 to 2.24) 0.593
Total −2.54 (−6.23 to 1.30) 0.183 −1.38 (−5.98 to 3.45) 0.555
Male −1.09 (−5.84 to 3.91) 0.651 0.588 −3.86 (−10.78 to 3.61) 0.289 0.213
Female −3.65 (−11.17 to 4.51) 0.355 2.55 (−4.25 to 9.83) 0.457
35–64 years old −5.46 (−10.76 to 0.16) 0.056 0.173 −4.17 (−19.92 to 14.68) 0.629 0.782
Ischaemic heart
diseases (I20–I25)
≥65 years old −0.44 (−5.00 to 4.35) 0.848 −1.62 (−6.29 to 3.29) 0.497
Total 0.78 (−6.55 to 8.69) 0.834 −2.48 (−12.69 to 8.92) 0.644
Male 2.83 (−5.94 to 12.41) 0.525 0.489 −4.81 (−16.49 to 8.51) 0.446 0.624
Female −1.72 (−10.36 to 7.76) 0.701 −0.22 (−12.79 to 14.16) 0.973
35–64 years old 8.87 (−0.60 to 19.24) 0.066 0.071
Cerebrovascular
diseases (I60–I69)
≥65 years old −1.97 (−8.44 to 4.97) 0.555 −4.14 (−12.89 to 5.49) 0.372
Total 5.86 (−9.78 to 24.22) 0.469 −5.43 (−12.55 to 2.27) 0.154
Male −3.83 (−20.79 to 16.77) 0.682 0.273 −1.02 (−13.59 to 13.38) 0.878 0.447
Female 10.49 (−5.33 to 28.94) 0.195 −7.46 (−16.95 to 3.11) 0.153
35–64 years old 8.03 (−8.91 to 28.12) 0.359 0.729 0.504
Hypertensive disorders
(I10–I15)
≥65 years old 3.53 (−12.60 to 22.64) 0.676 −4.65 (−11.63 to 2.87) 0.208
Total 2.46 (−5.72 to 11.36) 0.552 6.09 (−8.62 to 23.17) 0.422
Male 9.54 (−5.40 to 26.84) 0.212 0.116 7.73 (−15.73 to 37.71) 0.538 0.877
Female −4.03 (−11.03 to 3.51) 0.273 5.33 (−9.04 to 21.97) 0.473
35–64 years old −2.75 (−17.39 to 14.47) 0.727 0.456
Arrhythmia (I47–I49)
≥65 years old 4.28 (−4.19 to 13.51) 0.317 6.37 (−7.88 to 22.82) 0.385
Total −2.41 (−15.57 to 12.81) 0.731 −5.98 (−14.47 to 3.37) 0.192
Male 0.23 (−10.94 to 12.81) 0.968 0.695 −11.13 (−24.40 to 4.47) 0.145 0.366
Female −4.27 (−21.42 to 16.62) 0.652 −2.23 (−14.10 to 11.27) 0.722
35–64 years old 9.40 (−8.89 to 31.35) 0.321 0.247
Congestive heart failure
(I50)
≥65 years old −4.67 (−17.49 to 10.13) 0.501 −4.96 (−14.01 to 5.04) 0.305
Total 0.03 (−5.67 to 6.06) 0.993 −8.20 (−15.18 to −0.64) 0.035
Male −0.37 (−6.27 to 5.90) 0.901 0.894 −6.31 (−16.82 to 5.53) 0.270 0.753
Female 0.24 (−6.16 to 7.08) 0.941 −9.12 (−21.54 to 5.28) 0.193
35–64 years old 5.19 (−2.02 to 12.93) 0.154 0.119 0.334
Respiratory diseases
(J)
≥65 years old −2.47 (−8.43 to 3.89) 0.423 −7.38 (−14.81 to 0.69) 0.070
Total −2.08 (−9.85 to 6.35) 0.604 −13.86 (−22.27 to −4.54) 0.006
Male −0.02 (−9.89 to 10.92) 0.996 0.853 −13.50 (−28.03 to 3.96) 0.117 0.966
Female −1.74 (−15.50 to 14.26) 0.812 −13.02 (−26.62 to 3.10) 0.103
35–64 years old 1.44 (−13.68 to 19.20) 0.857 0.518
COPD (J40–J44, J47)
≥65 years old −4.34 (−11.17 to 3.02) 0.229 −13.39 (−21.71 to −4.18) 0.007
Total 7.26 (−13.42 to 32.87) 0.506
Male
Female 12.31 (−13.68 to 46.12) 0.372
35–64 years old
Asthma (J45–J46)
≥65 years old
Total 0.22 (−8.92 to 10.28) 0.962 −5.71 (−20.71 to 12.15) 0.492
Male −0.88 (−9.94 to 9.08) 0.851 0.709 −8.41 (−26.62 to 14.31) 0.422 0.710
Female 1.77 (−7.93 to 12.49) 0.721 −3.22 (−19.77 to 16.74) 0.722
35–64 years old 6.00 (−7.50 to 21.47) 0.386 0.358
Pneumonia (J12–J18)
≥65 years old −1.74 (−9.91 to 7.18) 0.681 −3.79 (−19.78 to 15.38) 0.665
COPD = chronic obstructive pulmonary disease; ICD-10 = International Classification of Diseases Tenth Revision
* Canton Aargau was excluded from the meta-analysis of cardiovascular diseases, ischaemic heart disease, cerebrovascular diseases; Canton Bern was excluded from
the meta-analysis of hypertensive disorders, arrhythmia, congestive heart failure.
† Test of interaction between the estimates of each gender- and age-category (z-score test).
Statistically significant results (p <0.05) are in bold type.
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Table S5: Gender- and age-specific estimates in change in risk (and 95% confidence interval) of hospital admission in adults (≥35 years old) due to acute myocardial
infarction (total, with ST-elevation, without ST-elevation) after the introduction of the smoking ban (data restricted to period of 2 years before and 2 years after the
introduction of the smoking ban in each canton).
Cause of hospital admission
(ICD-10 codes in parentheses)
% change (95% CI) p-value
Overall −2.55 (−9.30 to 4.70) 0.47
Male −1.32 (−9.31 to 7.38) 0.75
Female −2.27 (−12.4 to 9.06) 0.67
35–64 years −4.84 (−13.0 to 4.11) 0.27
Acute myocardial infarction (I21)
≥65 years −0.89 (−8.53 to 7.40) 0.82
Overall −4.76 (−11.2 to 2.15) 0.16
Male −7.25 (−13.2 to −0.95) 0.03
Female 2.80 (−13. 6 to 22.3) 0.75
35–64 years −6.14 (−15.1 to 3.73) 0.20
AMI STEMI (I210–I213)
≥65 years −2.05 (−10.2 to 6.85) 0.63
Overall 2.23 (−9.36 to 15.3) 0.71
Male 8.26 (−7.81 to 27.1) 0.32
Female −5.74 (−19.6 to 10.5) 0.45
35–64 years 0.83 (−14.9 to 19.5) 0.92
AMI NSTEMI (I214)
≥65 years 1.92 (−9.66 to 15.0) 0.75
AMI = acute myocardial infarction; ICD-10 = International Classification of Diseases Tenth Revision; NSTEMI = non-ST-elevation myocardial infarction; STEMI = ST-
elevation myocardial infarction
Canton Aargau was excluded from the meta-analysis.
Table S6: Description of the children included and estimates of change in risk after the introduction of the smoking ban in infant mortality (<1 year of age) and respiratory
hospital admission in children (≤15 years) (series restricted to period of 2 years before and 2 years after the introduction of the smoking ban in each canton).
Cause of hospitalisation or death
(ICD-10 codes in parenthesis)
N / %* Monthly mean N† (SD) % change
(95% CI)
p-value
Infant mortality (all) 1 160 1.4 (1.9) −16.6
(−42.5 to 21.1)
0.32
Due to perinatal conditions (P00–P96) 57.5% 0.8 (1.3) −6.7
(−39.2 to 43.4)
0.74
Children respiratory hospital admission (J) 35 271 27.7 (36.7) 3.6
(−7.2 to 15.5)
0.52
Respiratory infections (J00–J22) 83.2% 23.1 (31.7) 2.7
(−9.7 to 16.7)
0.68
CI: confidence interval; ICD-10 (International Classification of Diseases Tenth Revision) SD: standard deviation,
† Relative frequency related to the total number of cases due to each specific cause
* Mean monthly number of cases in each canton
Infant mortality: excluded cantons (AI, AR, GL, JU, NW, OW, SH, TG, UR, ZG) because mean monthly count below 0.5. Remaining cases accounting for 93.5% in total,
95.5% in only due to perinatal conditions.
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Table S7: Change (and 95% confidence interval) in hospital admissions and mortality due to ischaemic heart diseases and chronic obstructive respiratory diseases in
adults (≥35 years old) after the introduction of the smoking ban, by type of law and smoking profile of the canton (adjusted for the socioeconomic and health profile of the
population). Results shown in figure 3.
Hospital admissions Mortality
% change
(95% CI)
p-value int* % change
(95% CI)
p-value int*
Ischaemic heart diseases Overall −2.54 (−6.23 to 1.30) 0.18 −1.38 (−5.98 to 3.45) 0.56
Federal law 0.49 (−8.60 to 10.5) 0.54 −5.94 (−14.72 to 3.75) 0.26Type of law
Fed law + restr −3.13 (−8.19 to 2.21) 1.19 (−5.23 to 8.06)
Increase or equal 0.26 (−5.11 to 5.93) 0.20 −0.92 (−7.37 to 5.98) 0.89Change in active smoking
Decrease −6.90 (−14.4 to 1.23) −1.92 (12.34 to 9.74)
Below or equal median 2.30 (−3.26 to 8.18) 0.04 4.81 (−1.91 to 12.0) 0.02Decrease in ETS exposure
Above median −6.34 (−11.2 to −1.21) −6.81 (−12.20 to −1.08)
COPD Overall −2.08 (−9.85 to 6.35) 0.60 −13.9 (−22.3 to −4.54) <0.01
Federal law 9.14 (−7.05 to 28.2) 0.17 −16.6 (−34.1 to 5.45) 0.82Type of Law
Fed law + restr −5.34 (−13.7 to 3.83) −13.8 (25.2 to −0.70)
Increase or equal −2.05 (−11.5 to 8.41) 0.79 −15.6 (−27.1 to −2.30) 0.81Change in active smoking
Decrease 0.95 (−15.3 to 20.4) −12.1 (−32.3 to 14.1)
Below or equal median −1.43 (−12.4 to 10.9) 0.95 −16.8 (−29.8 to −1.43) 0.69Decrease in ETS exposure
Above median −0.92 (−11.6 to 11.1) −12.8 (−25.3 to 1.87)
CI = confidence interval; COPD = chronic obstructive pulmonary disease; ETS = environmental tobacco smoke
Type of smoking ban: Federal law = cantons which followed only the federal smoking Ban; Fed. law + restr = cantons which applied additional restrictions to the federal
smoking ban.
Change in active smoking: difference between the reported smoking prevalence in the Swiss Health Surveys of 2007 and 2012 (active smoker if positive answer to the
question: “Do you usually smoke?”). Stratified by non-decrease vs decrease in prevalence.
Decrease in ETS exposure: difference between the reported ETS exposure in the Swiss Health Surveys of 2007 and 2012 (exposed to ETS if answering at least 1 hour to
the question “How much time are you exposed to smoke everyday?”). Since there was always a decrease, cantons were classified according to whether the decrease was
above or below the median value.
*Test of interaction (z-score) p-value.
Table S8: Sensitivity analysis.
Hospital admissions* Mortality
% change
(95% CI)
p-value % change
(95% CI)
p-value
Ischaemic heart disease
Main −2.54 (−6.23 to 1.30) 0.18 −1.38 (−5.98 to 3.45) 0.55
SA1 Control trend with control outcome −3.06 (−6.89 to 0.92) 0.12 −0.20 (−5.08 to 4.93) 0.94
SA2 Study period 2005–2012 0.85 (−5.67 to 7.82) 0.80 −1.86 (−4.98 to 1.36) 0.24
SA3 All cantons −1.14 (−5.93 to 3.89) 0.64 na
SA4 SB 1 year before 0.06 (−9.96 to 11.2) 0.99 −4.66 (−10.3 to 1.28) 0.12
COPD
Main −2.08 (−9.85 to 6.35) 0.60 −13.9 (−22.3 to −4.54) 0.01
SA1 Control trend with control outcome −1.39 (−9.01 to 6.85) 0.72 −14.4 (−22.5 to −5.41) <0.01
SA2 Study period 2005–2012 1.00 (−7.76 to 10.6) 0.82 −5.78 (−10.9 to −0.38) 0.04
SA3 All cantons na na
SA4 SB 1 year before −19.8 (−32.8 to −4.28) 0.02 −1.29 (−22.1 to 25.2) 0.91
SA5 Outcome not smoking-ban related† 1.29 (−2.14 to 4.84) 0.45 −1.71 (−7.45 to 4.39) 0.56
CI = confidence interval; COPD = chronic obstructive pulmonary disease; na = not applicable; SB = smoking ban
SA1: include monthly count of control outcome to additionally adjust time trend; SA2: study period 2005–2012 (not restricted to 2 years before and after the introduction of
the smoking ban); SA3: all cantons (canton Argau not excluded); SA4: Smoking ban introduced 1 year before (excluded canton of Ticino) and restricted to the period of 1
year before and 1 year after introduction of the smoking ban.
* Canton Aargau excluded for ischaemic heart disease
† Outcomes not smoking-ban related: deaths due to external causes (V01–Y98), hospital admission due to injuries (S00–S98).
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Figure S1
Scheme of the selection of the 2-year period before/after (red) the date of introduction of the smoking ban (blue) per canton.
Canton abbreviations: Aargau (AG); Appenzell Innerrhoden (AI); Appenzell Ausserrhoden (AR); Bern (BE); Basel-Landschaft (BL); Basel-
Stadt (BS); Fribourg (FR); Geneva (GE); Glarus (GL); Graubünden (GR); Jura (JU); Luzern (LU); Neuchâtel (NE);Nidwalden (NW);
Obwalden (OW); St. Gallen (SG); Schaffhausen (SH); Solothurn (SO); Schwyz (SZ); Thurgau (TG); Ticino (TI); Uri (UR); Vaud (VD); Valais
(VS); Zug (ZG); Zurich (ZH).
Figure S2
Time-series plots of the monthly counts (2005–2012) of the outcomes excluded from the metaregression analysis for Bern and Aargau.
CDV = cardiovascular disease; IHD = ischaemic heart disease
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Figure S3
Forest plots of the overall and canton-specific results for ischaemic heart disease (IHD) and chronic obstructive pulmonary disease (COPD)
hospitalisations and mortality in adults ≥35 years old after the introduction of the smoking ban. (Canton Argau was excluded from IHD
hospital admission analysis.)
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Figures (large format)
Figure 1
Geographical distribution of the two types of smoking ban implemented in each canton in Switzerland. Fed. Law (light grey): cantons which
followed only the Federal Smoking Ban; Fed. Law + restrictions (dark grey): cantons which applied additional restrictions to the Federal
Smoking Ban.
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Figure 2
Gender- and age-specific estimates of percentage (and 95% confidence intervals, CIs) change in hospital admissions and mortality in adults
(≥35 years old) by the main groups of causes after the introduction of the smoking ban (data restricted to the periods 2 years before and 2 years
after the introduction of the smoking ban in each canton).
COPD = chronic obstructive pulmonary disease; SB = smoking ban
Hospital admissions: Canton Aargau was excluded from the meta-analysis of cardiovascular diseases, ischaemic heart disease,
cerebrovascular diseases; Canton Bern was excluded from the meta-analysis of hypertensive disorders, arrhythmia, congestive heart failure.
Original article Swiss Med Wkly. 2016;146:w14381
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 16 of 17
Figure 3
Change (and 95% confidence interval, CI) in hospital admissions and mortality due to ischaemic heart disease and chronic obstructive
pulmonary disease (COPD) in adults (≥35 years old) after the introduction of the smoking ban, by type of law and smoking profile of the canton
(adjusted for the socioeconomic and health profile of the population).
SB = smoking ban.
Type of law: Fed. Law = cantons which followed only the federal smoking ban, Fed. Law + restr = cantons which applied additional restrictions
to the federal smoking ban.
Change in active smoking: difference between the reported smoking prevalence in the Swiss Health Surveys of 2007 and 2012. Stratified by
non-decrease vs decrease in prevalence.
Decrease in environmental tobacco smoke (ETS) exposure: difference between the reported ETS exposure in the Swiss Health Surveys of 2007
and 2012. Since there was always a decrease, cantons were classified according to whether the decrease was above or below the median
value.
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